SUMMARY Synthetic atrial natriuretic factor (ANF) was administered in ascending doses (0.03, 0.20, 0.45 /Lig/kg/min) to eight mildly essential hypertensive men on high (200 mEq/day) or low (10 mEq/day) sodium diets. Responses of blood pressure, heart rate, urinary volume and electrolyte excretion, renin, and aldosterone were measured. For the entire group, ANF lowered blood pressure and increased heart rate during the 0.20 and 0.45 ju,g/kg/min infusions, and the antihypertensive effect of the peptide persisted for at least 2 hours after the infusions ended. Four patients (2 at 0.20 jtxg/kg/min and 2 at 0.45 ptg/kg/min) experienced sudden bradycardia and hypotension at the end of or shortly after completion of ANF infusion. Renal excretion of water, sodium, chloride, calcium, and phosphorus increased in a dose-dependent fashion in response to infused ANF. Patients on the 200 mEq/day sodium diet had greater increases in urinary volume (11.1 ± 2.8 vs 3.0 ±2.0 ml/min; p<0.05), sodium (870 ± 134 vs 303 ± 27 /xEq/min; p<0.05), and chloride (801 ± 135 vs 176 ± 75 juEq/min; p<0.02) compared with patients on the low sodium diet. The apparent direct suppressive effect of a 0.03 /xg/kg/min infusion of ANF on renin and aldosterone levels was overcome at higher doses by counterregulation provoked by the depressor action. Renin was slightly (-12%) suppressed during the 0.03 /xg/kg/min infusion of ANF but increased at the 0.20 ( + 50%) and 0.45 /ng/kg/min ( + 90%; p<0.03) rates. Aldosterone declined significantly during the 0.03 jug/kg/min infusion ( -4 5 % ; p<0.01) of ANF but not during the two higher dose infusions. There were no significant differences in renin and aldosterone responses for the 200 mEq/day and 10 mEq/day sodium diets. We conclude that the depressor action of 1-hour infusions of very high doses of synthetic ANF in essential hypertensive men is associated with a high risk of late hypotension. Dietary sodium restriction diminishes the peak natriuretic effect of infused ANF but does not significantly affect responses of blood pressure, heart rate, renin, or aldosterone. 8 Such a pharmacodynamic profile would be very attractive in an antihypertensive drug, and studies of the cardiovascular actions of ANF in humans have been the subject of several recent reports. Initial human studies using bolus injections (100 /ig) confirmed the vasodepressor action of the peptide 9 but also suggested that the effect on arterial pressure is attenuated in hypertension.
doses (0.01-0.05 /u,g/kg/min) for 30 to 60 minutes do not significantly lower blood pressure in normal volunteers,"" 14 , but at higher infusion rates (0.10-0.60 /u.g/kg/min) sustained depressor effects are consistently observed. l3~16 At these higher infusion rates, however, adverse reactions, including bradycardia and hypotension, may occur.
14 " 17 Janssen et al. 17 suggested that the vasodepressor action of ANF is enhanced by sodium depletion and that symptomatic hypotension occurs frequently in salt-depleted subjects. However, others have not found a significant effect of dietary sodium restriction on the blood pressure response to ANF infusion. 1218 The present study was undertaken to evaluate the effect of differences in dietary sodium intake on blood pressure, heart rate, hormonal, and renal responses to 1-hour synthetic ANF infusions ranging from low (0.03 /u.g/kg/min) to high (0.45 /xg/kg/min) doses in essential hypertensive men.
ANF INFUSION IN HYPERTENSIVE MEWWeder et al.

Patients and Methods
Eight men between the ages of 20 and 55 years were recruited from the University of Michigan Hypertension Clinic (Ann Arbor, MI, USA) and by public advertisement. All patients had mild hypertension by history but were free of other known cardiovascular, renal, endocrine, or liver disease and were within 30% of ideal body weight. All medications were withdrawn, and blood pressure was measured weekly by an experienced nurse with cuff and stethoscope in the Hypertension Clinic with the patient in the seated position after 10 minutes of quiet rest. Patients with average diastolic blood pressure readings between 95 and 104 mm Hg for 3 weeks (beginning a minimum of 2 weeks after last antihypertensive therapy) were accepted into the study and were randomized to receive either 200 mEq or 10 mEq of sodium per day. All patients were informed of the details of the protocol and signed an informed consent previously approved by the University of Michigan Human Use Committee.
Outpatient Phase
Patients began eating the controlled diets as outpatients in the Clinical Research Center (CRC) of the University of Michigan, and dietary compliance was monitored by CRC dietitians. Both low and high sodium diets were isocaloric and contained equivalent amounts of potassium, calcium, phosphorus, and magnesium. Water was permitted ad libitum. Weight, blood pressure, heart rate, and urinary creatinine, sodium, and potassium (24-hour collections) were monitored for the first 4 days of the controlled diet, and patients demonstrating good dietary compliance on the fourth day of the diet (sodium excretion: 200 ± 30 mEq/day on 200 mEq sodium intake, <30 mEq/day on 10 mEq sodium intake) were admitted on the fifth day of the dietary intervention to the inpatient unit of the CRC.
Inpatient Phase
Infusion of the placebo was undertaken on the sixth day of the diet, and fixed-order ascending-dose infusions of ANF (0.03, 0.20, and 0.45 jAg/kg/min) administered on the seventh, ninth, and eleventh days. At 0800 on each infusion day, following placement of an 18-gauge blood sampling catheter and a 21 -gauge infusion catheter, patients were asked to void and were then given an oral loading dose of distilled water (20 ml/kg). Patients maintained a supine posture except when voiding and fasted throughout the infusion. Urine was collected every 30 minutes by voiding, and a replacement volume of water equal to the urine output plus 1 ml/min (insensible loss) was administered orally. This procedure was continued until a steady state, defined as two consecutive 30-minute excretion rates within 1 ml/min, was achieved. Baseline blood studies were obtained for renin, aldosterone, ANF, and electrolytes, and continuous infusion of either placebo or synthetic ANF was begun (Minute 0). Urine was collected by voiding every 20 minutes for 3 hours, and water was replaced at a rate equal to the steady state flow plus 1 ml/min for insensible loss. Plasma for ANF was obtained 30 minutes after beginning the infusion. At the end of the infusion (60 minutes) blood was sampled for renin, aldosterone, ANF, and electrolytes. The infusion was terminated, and two postinfusion ANF samples (65 and 75 minutes after the start of the infusion) were obtained. In addition to volume, creatinine, sodium, potassium, chloride, calcium, and phosphorus were measured in each aliquot of urine.
Blood pressure was monitored by cuff every 5 minutes during the infusion and every 10 minutes after infusion. Heart rate was determined from a lead II electrocardiogram monitored continuously for the 3-hour period.
Drug Infusion
WY-47663, a 25 amino acid peptide synthesized by a solid-phase technique, was obtained from Wyeth Laboratories (Philadelphia, PA, USA) in ampules containing 50 or 100 /xg of peptide in 0.005 M acetic acid. This peptide corresponds to the 102-126 amino acid sequence of the predominant human form, human ANF-(99-126), differing only by the absence of three amino terminal amino acids. The synthetic ANF is presumed to have completely equivalent biological potency to the endogenous peptide. The drug was reconstituted in 5% dextrose in water (D5W) on the day of the infusion at a concentration required to deliver the 60-minute infusion in 15 to 20 ml. Placebo and drug infusions were administered by syringe pump (Model 2716, Harvard, South Natick, MA, USA).
Analytical Methods
Seven milliliters of whole blood was collected in prechilled Vacutainer tubes containing EDTA and was centrifuged at 1500 g for 15 minutes at 4°C (Beckman TJ-6 centrifuge, Palo Alto, CA, USA) within 10 minutes of collection. Plasma was immediately transferred to polypropylene tubes, frozen in a dry ice-acetone bath, and stored at -20°C until shipment on dry ice to Wyeth Laboratories for assay. ANF was assayed by radioimmunoassay in unextracted plasma using an antibody purchased from Peninsula Laboratories (Belmont, CA, USA) that detects the carboxyl end of ANF and therefore will detect the amino terminal-depleted synthetic hormone used in this study. Human ANF purchased from Peninsula was used as a standard, and 123 I-labeled human ANF purchased from Amersham (Arlington Heights, IL, USA) was employed as a tracer. The sensitivity of the assay is about 2 pg/tube, with an interassay variation of 8.6% and an intraassay variation of 8.1%. Concentrations of endogenous immunoreactive ANF in plasma samples obtained from 28 healthy subjects on unrestricted diets ranged from 6.7 to 39.4 ng/dl (mean ± SEM, 15.6 ± 0.6 ng/dl).
Plasma renin activity was measured by radioimmunoassay of angiotensin I (Ang I) generated by a 60-minute incubation of plasma in the presence of excess substrate at pH 6.0." Plasma aldosterone levels were measured by radioimmunoassay using an antiserum directed against aldosterone-y-lactone. VOL 10, No 6, DECEMBER 1987 
Statistical Methods
Data were filed and stored on the Michigan Terminal System of the University of Michigan and analyzed with the MIDAS statistical package. Group comparisons of continuous variables were made by paired and unpaired t tests, as appropriate, and by the chi-square test for categorical variables. Statistical significance was accepted at the 0.05 level. When multiple comparisons were made between different doses at sequential time points, Bonferroni's correction was applied to determine statistical significance. Values for blood pressure, heart rate, plasma renin, aldosterone, ANF, and changes in urinary water and electrolyte excretion during active drug infusions were always compared with time-matched placebo values or responses.
Results
Effects of Dietary Sodium Control
There were no significant differences in age, weight, height, blood pressure, or heart rate between patients randomized to the '200 mEq and 10 mEq sodium diets (Table 1) . Patients assigned tq the 10 mEq sodium diet lost a significantly (p < 0.05) gTeater amount of weight than those on the 200 mEq sodium diet, but changes in blood pressure and heart rate during the preliminary dietary regimen were not significantly different. Urinary sodium and chloride were stable over the first 4 days of the controlled diet in the 200 mEq sodium diet group and showed the expected monoexponential decline in patients assigned to the 10 mEq sodium diet. Values for the 24-hour urinary collection on the fourth day of the diet are shown in Table 1 .
At baseline, immediately before the placebo infusion, there were no significant differences in plasma electrolytes or in levels of renin (3.4 ±0.6 vs 4.3 ± 1.0 ng Ang I/ml/hr) or ANF (22 ± 3 vs 18 ± 4 ng/dl) for the 200 mEq/day sodium diet versus the 10 mEq/day sodium diet. 
ANF Infusion
Plasma levels of ANF at baseline, after 30 and 60 minutes of drug infusion, and 5 and 15 minutes after infusion are shown in Figure 1 . For any dose, ANF levels at 30 and 60 minutes were not significantly different, and average plasma levels correlated significantly with the dose infused (30 minutes: r = 0.99, p<0.0001; 60 minutes: r = 0.96, p<0.0001). There were no significant differences in plasma ANF levels achieved during infusion between die 200 and 10 mEq sodium dietary groups. Plasma ANF levels at 5 and 15 minutes after completion of the infusion showed an apparent monoexponential decline, with a calculated plasma half-life of 5.6 minutes.
Cardiovascular Responses
Infusion of ANF caused dose-dependent decreases in blood pressure and increases in heart rate in all subjects ( Figure 2 ). Compared with the placebo infusion, effects on mean arterial blood pressure and heart rate were significant at both the 0.20 and 0.45 /xg/kg/ min doses. Significant depressor responses persisted for the 2 hours of observation following the end of drug infusion, while heart rate returned to levels not significantly different from placebo. There were no significant differences in mean arterial pressure or heart rate responses between patients ingesting 200 mEq/day and 10 mEq/day sodium.
Four patients experienced adverse cardiovascular reactions, one high sodium and one low sodium diet patient at the 0.20 /ig/kg/min dose and two low sodium diet patients at the 0.45 pig/kg/min dose ( Table 2 ). All reactions occurred at the end of the drug infusion or within a few minutes of terminating a completed infusion. Subjects were asymptomatic during the infusion, but after the sudden onset of bradycardia and hypotension, all complained of lightheadedness, nausea, and weakness, and one also experienced a throbbing headache. Patients were placed in Trendelenburg's position and generally recovered spontaneously within a few minutes. One patient was treated with 0.75 mg of atropine i.v. for bradycardia. No subject suffered any prolonged adverse effect.
Patients were subgrouped according to their sensitivity to hypotension and bradycardia (Table 3) : Group 1 had no adverse reactions, Group 2 had adverse responses only after the 0.45 /ng/kg/min dose, and Group 3, those patients most sensitive to the adverse effect, had reactions at the 0.20 pig/kg/min dose. There were no obvious differences among the three groups for blood pressure, heart rate, plasma electrolytes, renin, aldosterone, or ANF during the placebo or the 0.03 /ig/kg/min infusions that would have predicted subsequent adverse reactions. During the 0.20 /i.g/kg/min infusion, Group 3 patients (i.e., those patients who became hypotensive after that infusion) had greater depressor responses than patients who either never experienced hypotension (Group 1) or those who became hypotensive only at a higher dose (Group 2). Despite the stimulus of this greater depressor response, Group 3 patients had only weak counterregulatory heart rate, renin, and aldosterone responses. In contrast, Group 2 patients, whose depressor responses were similar to those of Group 1, evidenced vigorous counterregulation. A tendency for vigorous heart rate, renin, and aldosterone responses was also observed in the Group 2 patients during the 0.45 /ig/kg/min infusion, but at that high infusion rate, the effects of ANF apparently overcame the subject's counterregulatory capacity.
Renal Responses
As shown in Figure 3 , infusion of ANF produced dose-dependent increases in urine volume and in the excretion of sodium, chloride, phosphorus, and cal-"°--n TME (rrtnutw) cium. There were small increases in the excretion of potassium, but the changes were not statistically significant. There were no statistically significant changes in creatinine excretion or clearance during the infusions. There were no significant differences between the high sail and low salt diet groups except during the 0.45 ^ig/kg/min infusion, which produced significantly greater increments in urinary volume (11.1 ±2.8 vs 3.0±2.0 ml/min;p<0.05) and sodium (870 ± 134 vs 303 ± 27 /xEq/min; p<0.05) and chloride (801 ± 135 vs 176 ± 75 /iEq/min; p<0.02) excretion in the high salt diet group. These changes reflected a fivefold increase in the sodium excretion rate over the placebo infusion day for the high sodium Values are means ± SEM. Group 1 = no hypotension or bradycardia (n = 4);Group2 = hypotension or bradycardia at ANF, 0.45 /ig/kg/min (n = 2); Group 3 = hypotension or bradycardia at ANF, 0 20 /ig/kg/min (/i = 2).
diet and an 11 -fold increase for the low sodium diet group. The effect of ANF on renal ion excretion was short-lived except for the increase in urinary sodium excretion, which remained greater than the change produced by placebo for the first hour after discontinuation of the infusion at the two highest doses (0.20 /Ag/kg/min: Na + excretion 63% above placebo, /?<0.02; 0.45 /ng/kg/min: Na + excretion 4 1 % above placebo, p < 0 . 0 5 ) . Sodium excretion returned to values not significantly different form those of the placebo day by the second hour after infusion.
Effect of ANF Infusion on Plasma Renin Activity and Aldosterone
The effects of ANF infusion on plasma levels of renin and aldosterone appear to be complex. There were no significant differences between the high and low salt diet groups for renin or aldosterone responses (baseline value [Minute 0] vs level at end of infusion [Minute 60]). For the entire group, plasma renin showed a slight, nonsignificant decline (-12%) during the 0.03 /Ltg/kg/min infusion but increases of 50 and 90% during the 0.20 and 0.45 /u.g/kg/min infusions, respectively, the latter change reaching significance (p<0.03). Aldosterone levels declined in all eight patients during the 0.03 //.g/kg/min infusion, and the average decrease of -4 5 % was significantly (p<0.0l) different from the placebo response. Responses of plasma aldosterone to the 0.20 and 0. 45 .g/kg/min doses were variable, and mean changes were not significantly different from placebo. Discussion The present study examined the effects of differences in dietary sodium intake on cardiovascular, renal, and endocrine responses to three graded 1-hour intravenous infusions of synthetic ANF in patients with mild essential hypertension. Our results confirm the previously reported antihypertensive, natriuretic, chloruretic, phosphaturic, and calciuric effects of ANF and also suggest a complex interaction of ANF with other systems regulating renin and aldosterone secretion. Also, as previously reported, 14 " 17 prolonged infusion of ANF at rather high doses (0.20 and 0.45 /ug/kg/ min) can cause sudden symptomatic hypotension and bradycardia. Dietary sodium restriction did not significantly affect the basal levels or the pharmacokinetics of ANF during infusion or the cardiovascular or endocrine responses to the drug. Our inability to detect the increase in endogenous circulating ANF in response to a high sodium intake that has been described by others 12 ' 2I probably reflects the presence of cross-reacting substances in unextracted plasma. 22 Such substances make only a minor contribution to the very high levels of immunoreactive ANF measured during and immediately after infusion of the synthetic hormone. Urinary volume and electrolyte excretion patterns were also similar for patients on the two diets, but natriuresis and diuresis were significantly greater during the highest dose of ANF in the high salt compared with the low salt diet group.
Infusion of ANF produced prompt and sustained dose-dependent reductions in blood pressure in all patients. Several groups have reported no significant effect on blood pressure or heart rate of low dose (<0.05 ^.g/kg/min) infusions of ANF in normal volunteers,"" 14 and consistent with those findings, effects on blood pressure or heart rate at the 0.03 /ig/kg/hr dose were not significant in our patients. Weidmann et al. 15 ' 18 did note definite depressor and tachycardic responses to administration of a bolus dose of 50 fj.g followed by an infusion of 0.1 /ig/kg/min, and Cody et al. 13 and Bussien et al. 16 have reported dose-dependent decreases in blood pressure during ANF infusions of 0.3 to 0.6 /ng/kg/min in normal men. Biollaz et al. 14 reported a depressor effect of a 5.0 yag/min infusion (approximately 0.07 pig/kg/min) in normal volunteers, but the response did not reach significance until the third hour of the infusion. The threshold for the vasodepressor response to continuously infused ANF would therefore appear to be between 0.05 and 0.10 /ig/kg/min. In our study, the two higher doses (0.20 and 0.45 /ng/kg/min) infused produced prompt antihypertensive responses that were sustained for 2 hours after the infusion terminated, well after plasma ANF levels had declined to baseline levels and renal volume and electrolyte excretions were no longer significantly above time-matched placebo controls. This prolonged antihypertensive effect has been noted in studies using high doses of ANF (0.3-0.6 ^g/kg/min) 16 or long infusion periods (0.07 ^ig/kg/min for 4 hours) 14 but not at 0.1 /Lig/kg/min for 45 minutes 18 and was seen both in patients who did and in those who did not experience symptomatic hypotension. Clearly, the antihypertensive effect of high doses of the hormone need not directly reflect plasma levels. In agreement with Cuneo et al. 12 and Weidmann et al., 18 we did not find that alterations in dietary sodium intake significantly affected blood pressure and heart rate responses to infused ANF.
The causes of the differences in susceptibility to the hypotensive-bradycardic responses we observed in four of our eight patients are unknown. Plasma levels of ANF achieved during infusion were similar in patients who did and in those who did not experience adverse reactions, but there were apparent differences in the cardiovascular effects of the drug. Patients who had no adverse reactions (Group 1) had the smallest depressor effect, while those who were most susceptible to the adverse effect (Group 3) also had the most pronounced depressor responses during infusion. Thus, there appears to be a substantial interindividual variability in blood pressure responsiveness to infused ANF that may be linked to the precipitating cause of hypotension and bradycardia. Three of the four reactions occurred in patients on the low salt diet, reinforcing the suggestion of Janssen et al. ' 7 that the effect might be related to blood volume depletion, although in the present study the interaction of diet and hypotension was not significant by chi-square analysis. Differences in renal excretion of water and ions were not predictive of hypotension, but since ANF may also promote shifts of fluid from the intravascular to the interstitial compartment, 4 progressive contraction of intravascular volume could still contribute to hypotension.
It does appear that effective counterregulatory responses may aid in the maintenance of blood pressure and help some patients avoid hypotension and bradycardia during ANF infusion. In this regard, Group 2 subjects had the greatest heart rate, renin, and aldosterone increases in response to ANF infusion at 0.20 /ng/kg/min and during that infusion experienced depressor responses similar to those of Group 1 patients. In contrast, Group 3 patients, who had only very small increases in heart rate and renin and marked decreases in aldosterone during the 0.20 /tg/kg/min infusion, had the largest depressor responses and subsequently progressed to hypotension. Depressor responsiveness probably reflects the net effect to the impact of the pharmacological effects of ANF on several physiological systems, and the adverse effects experienced by the Group 3 patients may not be the result of some intrinsic unresponsiveness of counterregulatory systems but rather may represent differences in interindividual susceptibility to the pharmacological effects of ANF at vascular, cardiac, and endocrine sites.
Finally, the relatively modest responses in heart rate to the depressor effect of infused ANF seem worthy of comment. We and others 12 ' 18 have interpreted the rises in heart rate seen during administration of ANF in doses sufficient to provoke depressor responses as being due to reflex sympathetic nervous system activation. However, a stimulatory effect of ANF on chemoreceptors linked to vagal afferents that results in sympathetic withdrawal has been described in rats. 23 The effects in humans of prolonged infusion of ANF on baroreceptor reflex sensitivity and sympathetic and vagal tone should be examined in future studies.
The renal effects of our ANF infusions were similar to those reported by others. 9 ' ' Oi 12> l3> l3> l8 Renal excretory responses were in general dose-related, and patterns were quite similar for the low salt and high salt diet patients. Only the changes in urinary volume and sodium and chloride excretion at the 0.45 jig/kg/min dose of ANF showed a significant effect of diet.
The dose-related responses of plasma renin and al- VOL 10, No 6, DECEMBER 1987 dosterone appeared to reflect both the direct effects of ANF on renin and aldosterone secretion and reflex responses provoked by the cardiovascular effects of the infusions. At the lowest dose, average renin levels declined slightly and aldosterone fell significantly. At the two high doses, which produced significant falls in blood pressure and increases in heart rate, renin activity rose, significantly at the 0.45 ptg/kg/min infusion rate. At these higher infusion rates, aldosterone responses were quite variable and changes were not significantly different from those observed during placebo. Cuneo et al. 12 reported suppression of aldosterone and renin during low dose (0.048 ^ig/kg/min) infusion of ANF that did not lower blood pressure or raise heart rate in normal subjects. Weidmann et al. 18 observed suppression of aldosterone but stimulation of renin at a dose range (0.1 /ng/kg/min) that significantly lowered blood pressure and raised heart rate. These results suggest that ANF has an action that suppresses renin and aldosterone secretion at ANF plasma levels near the upper range reported in patients with congestive heart failure"
113 ' 24 but that at pharmacological doses associated with plasma volume contraction, depressor responses, and possibly reflex sympathetic nervous system activation, the suppressive effects of ANF are overridden by other mechanisms. Elucidation of the contribution of ANF to the physiological regulation of renin and aldosterone secretion will probably have to await the development of ANF receptor-blocking agents.
The apparent plasma half-life of ANF following discontinuation of the infusion calculated from our data (5.6 minutes) is longer than that reported by Yandle et al. (3.1 minutes) . 25 Our estimate is based on only three time points in a small number of subjects, and assays were performed on unextracted plasma, but during these very high dose infusions, the hormone may have reached binding sites or physiological compartments with different pharmacokinetic characteristics.
In summary, 1-hour infusions of very high doses of ANF lowered blood pressure in essential hypertensive men but were associated with a high incidence of adverse effects. High dietary salt intake enhanced the natriuretic action of ANF but did not affect the doserelated antihypertensive effect. However, dietary salt restriction may increase the risk of sudden hypotension and bradycardia. Since regardless of sodium intake, marked diuresis, natriuresis, and aldosterone suppression occurred at an infusion rate below that which produced acute cardiovascular effects, potential exists for the development of ANF-like compounds with marked diuretic and natriuretic activity but without adverse cardiovascular impact. Such compounds would be expected to share a long-term antihypertensive action with conventional diuretics and might be even more effective than available agents if the antialdosterone and antirenin actions are retained.
